Melanotan II
Also known as Melanotan 2, Melanotan-II, MT-II, MTII, MT2
A synthetic cyclic peptide sold for tanning. Its human trials total 23 men between 1996 and 2000, and none of the regulators checked has approved it.
Melanotan II is a synthetic peptide of seven amino acids closed into a ring, made as an analogue of alpha-melanocyte stimulating hormone (alpha-MSH) and sold online as a tanning injection or nasal spray. Its published human record is three small studies in 23 men, run between 1996 and 2000 by one University of Arizona group: a pilot of skin darkening in 3 men, and two crossover studies of erections in 10 men each. None lasted longer than two weeks, none enrolled women, and none measured sunburn, skin cancer or body weight. It is listed here as in clinical trials because those controlled studies exist and because one phase 2 trial, registered in 2026, is recruiting, but that trial has reported nothing and no other trial since 2000 was found. None of the regulators checked has approved any product containing it, and the harms reported outside the trials come from case reports, which cannot show cause.
What it is, and what it is not
The structure its first human investigators published in 1996 is usually written Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. It carries an acetyl group at the start, norleucine (an amino acid outside the twenty the genetic code specifies), the D-form of phenylalanine, a lactam bridge that closes the ring between the aspartic acid and lysine side chains, and an amide at the end. None of that fits the one-letter code this site uses for sequences, so no sequence is given. The formula is C50H69N15O9 in FDA's substance registry. The same investigators describe it as a non-selective melanocortin receptor agonist, meaning it is not confined to one receptor type in that family.
Two approved drugs are often confused with it. Bremelanotide, known in research as PT-141 and sold in the United States as Vyleesi, has the same sequence and ring but a free acid in place of the amide at the end, according to its FDA label; a 2007 review with two of the Arizona investigators among its authors names it PT-141 and calls it "the carboxylate derivative of MT-II". No source found calls it a metabolite of Melanotan II. Afamelanotide, sold as Scenesse and listed in PubChem under the synonym Melanotan I, is a different and larger molecule of 13 amino acids, approved by FDA "to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)", according to its label. Neither approval covers Melanotan II, and neither drug's trials are evidence about it.
The literature does not always keep them apart. A 2003 article writes "PT 141 (Melanotan II)", and many case reports say only "melanotan" without saying which peptide was used.
What has been tested in people
The 1996 pilot gave Melanotan II or saline by injection on alternating days to 3 healthy men over two weeks. Two of the three had darker skin on the face, upper body and buttock a week after the last injection, measured by reflectance and by eye. It is the only measurement of pigmentation with Melanotan II itself, and it was not randomised.
The two erection studies tested men with erectile dysfunction in double-blind, placebo-controlled crossovers. In 10 men with psychogenic erectile dysfunction, 8 had clinically apparent erections after Melanotan II during six hours of monitoring. In 10 men with organic risk factors, erections followed 12 of 19 Melanotan II injections and 1 of 21 placebo injections. The same group later pooled the two as 20 men, which is the same 20 men rather than further evidence. No trial has tested sexual function in women or in men without erectile dysfunction.
Nausea, stretching and yawning were the side effects reported across all three studies, with spontaneous erections in the pilot and decreased appetite in the 1998 study. Severe nausea followed 4 of 19 Melanotan II injections in the 2000 study.
One newer trial is registered: NCT07437560, a randomised, placebo-controlled phase 2 study of Melanotan II alongside narrowband UV-B phototherapy in adults with stable nonsegmental vitiligo, at Peking University Shenzhen Hospital, sponsored by Hudson Biotech. It started in February 2026 and is recruiting, with 60 participants estimated, and no results are posted.
Sunburn and skin cancer
No human study of Melanotan II has measured either. The protective claims come from marketing. In an enforcement case against one seller, FDA records that the company's website linked to articles reporting that Melanotan II was developed for the purpose of protecting against skin cancer and rosacea, and Denmark's medicines agency described "Melanotan" as marketed as a tanning product offering protection against the sun and preventing skin cancer, while warning against it. Two people in the case reports below used Melanotan II together with tanning beds or a UV tanning studio.
What the case reports show, and what they cannot
Outside the trials, the evidence on harm is case reports: single patients who used unlicensed products, often alongside sunbeds or other drugs. A case report records that something happened to a person who had used a product. It cannot show that the product caused it, and no study has measured how often melanoma occurs in people who use Melanotan II.
The most recent melanoma report, from 2026, describes a 49-year-old man with five melanomas in situ who had used tanning beds, Melanotan II, Melanotan I and testosterone. Its authors write that "causality remains unproven", that the melanomas may have been preexisting and become visible because of pigment changes, and that his tanning bed use was "a major confounding variable". A 2025 report describes a 22-year-old woman who developed a mucosal malignant melanoma in the upper jaw after using a Melanotan II nasal spray for tanning, and titles itself as a question. A 2014 report describes a 20-year-old woman whose melanoma was excised three months after she had injected Melanotan II alongside sunbed tanning. A 2017 review counted four melanoma case reports and concluded that conclusive evidence linking them to melanotan is lacking. Mole changes are described in a teenager with an inherited multiple-mole syndrome who also used a tanning studio, and in a man with a history of melanoma whose new and darkened moles lightened after he stopped using a product described only as synthetic alpha-MSH.
Other reports describe priapism in a man who had not yet recovered erectile function four weeks later, priapism needing an operation after an injection of Melanotan II, and a man who developed muscle breakdown and kidney dysfunction after injecting Melanotan II bought online, confirmed by mass spectrometry, with opiates also found in his urine. FDA's safety text names melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism as serious events discussed in published case reports.
In the United Kingdom, the MHRA received 13 suspected adverse reaction reports associated with melanotan II between 2011 and 2021, and states that a report does not necessarily mean the drug caused the event.
What products contain
Measured products do not match their labels. Vials bought from three online shops held 4.32 to 8.84 mg of Melanotan II against a labelled 10 mg, and vials from two of the shops held 4.1 to 5.9% unknown impurities. In Australia, five seized nasal spray bottles with the same label contained an estimated 22 mg to 54 mg against a 30 mg label, according to a TGA advisory read in a browser by a person. Melanotan II also turns up in the same illicit supply as anabolic steroids: an analysis of eight police-seized samples intended for the bodybuilding black market identified it alongside bremelanotide. In the US enforcement case, FDA's proposal to debar the seller records that product advertised as "100% U.S. made" had in part been "manufactured in and imported from China".
Regulation
In the United States, FDA describes Melanotan II as "an unapproved new drug" in a 2016 debarment order. For compounding, it was previously in category 2, the bulk substances FDA says may present significant safety risks; the nomination was withdrawn, and FDA's safety-risks page still carries its concern about immunogenicity and serious case-report events. The 503A list of 14 May 2026 does not include it in any category, yet FDA's compounding advisory committee page lists it among substances being considered for the 503A bulks list at a meeting before the end of February 2027. No FDA document found explains the difference.
In Australia, the TGA says Melanotan II is a prescription-only medicine, not approved as a tanning agent, with no product on the Australian Register of Therapeutic Goods. In the United Kingdom the position is not a flat ban: in 2024 the MHRA said Melanotan II products are medicines if they are injectable or pens, that nasal sprays are medicines only if sold with claims to treat or prevent disease, and that unauthorised medicines may not be sold or supplied. A 2021 reply had been looser on injectables. Denmark's medicines agency warned in 2008 and again in 2011 against "Melanotan", without naming which peptide, as not authorised in Denmark, Europe or the United States. Ireland's medicines regulator, the HPRA, reported in March 2024 a concerning upward trend in detentions of Melanotan 2, which it called an unregulated substance promoted as a self-tanning aid.
What the research shows
Each statement below is labelled with the strongest kind of study supporting it, and links to that study.
- Human case reportSupportive / Very low confidence
Given by subcutaneous injection in a single-blind, saline-controlled pilot, Melanotan II increased skin pigmentation in 2 of 3 men, measured one week after treatment ended.
Three healthy men received Melanotan II or saline on alternating days over two weeks. Two had increased pigmentation in the face, upper body and buttock, measured by reflectance and by eye a week after the last injection. Mild nausea, stretching and yawning, and spontaneous erections lasting 1 to 5 hours were reported.
One or a few individual cases. Cannot show whether an effect is general.
- Route: subcutaneous injection.
- Three men, not described as randomised. This is the only pigmentation evidence for Melanotan II itself.
- Run in 1996 by University of Arizona investigators, with National Cancer Institute funding. The same group ran all three trials, and no independent group has repeated them.
- It measured skin colour, not protection from sunburn or skin cancer.
- Only the abstract was read.
- Human case reportSupportive / Low confidence
Given by injection in a double-blind, placebo-controlled crossover in 10 men with psychogenic erectile dysfunction, Melanotan II was followed by clinically apparent erections in 8 of the 10.
Erections were monitored with a RigiScan device over six hours. Mean duration of tip rigidity above 80% was 38.0 minutes with Melanotan II and 3.0 minutes with placebo (p=0.0045). Nausea, stretching and yawning, and decreased appetite were reported more often after Melanotan II than placebo, and none required treatment.
One or a few individual cases. Cannot show whether an effect is general.
- Route: injection; the abstract does not say which kind.
- The abstract does not say the order of treatments was randomised, and PubMed indexes it as a controlled clinical trial rather than a randomised one, so it is graded below an RCT here.
- Ten men, all with erectile dysfunction of no known organic cause, monitored for hours rather than weeks.
- Published in 1998 by the same University of Arizona group. Only the abstract was read.
- Human case reportSupportive / Low confidence
Given by subcutaneous injection in a double-blind, placebo-controlled crossover in 10 men with erectile dysfunction and organic risk factors, Melanotan II produced longer rigid erections than placebo.
Each man received two active and two placebo injections. Erections were reported after 12 of 19 Melanotan II injections and 1 of 21 placebo injections, and mean tip rigidity above 80% lasted 45.3 minutes against 1.9 (P = 0.047). Sexual desire was rated higher after Melanotan II. Severe nausea followed 4 of 19 Melanotan II injections.
One or a few individual cases. Cannot show whether an effect is general.
- Route: subcutaneous injection.
- Ten men. The results are counted per injection, not per man.
- PubMed indexes it as a randomised controlled trial, but the abstract never says the treatment order was randomised, so it is graded the same as the 1998 study.
- Published in 2000 by the same University of Arizona group. Only the abstract was read.
- The group's own review pools this study with the 1998 one as 20 men. That pooled figure is the same 20 men, not additional evidence.
- Human case reportInsufficient evidence / Very low confidence
Case reports describe melanoma and melanoma in situ in people who had used Melanotan II, often alongside sunbeds, but they cannot show that it caused them, and no study has measured melanoma incidence in users.
A 49-year-old man with tanning bed use, Melanotan II, Melanotan I and testosterone exposure had five melanomas in situ arising in severely dysplastic moles; his authors write that causality "remains unproven". A 22-year-old woman who used a Melanotan II nasal spray for tanning developed a mucosal malignant melanoma in the upper jaw. A 20-year-old woman who had injected Melanotan II to augment sunbed tanning had a melanoma excised three months later. A 2017 review counted four case reports of melanoma emerging from existing moles during or shortly after melanotan use, and concluded that conclusive evidence linking them is lacking.
One or a few individual cases. Cannot show whether an effect is general.
- Routes: injection and nasal spray, self-administered with unlicensed products. The 2026 patient injected it; the 2014 patient self-injected it.
- Single patients. A case report documents that an event happened after use, not that the product caused it.
- The 2026 authors name frequent tanning bed use as "a major confounding variable" and testosterone use as "an additional potential confounder", and say the melanomas may have been preexisting and "became clinically apparent due to pigmentary changes rather than arising de novo".
- The 2025 report frames its own title as a question: a possible risk factor.
- Human case reportInsufficient evidence / Very low confidence
Case reports describe new, darkening or atypical moles after self-injection of alpha-MSH analogues, including one in which the moles lightened after use stopped.
A 40-year-old man with a history of melanoma who injected synthetic alpha-MSH developed crops of new moles, many atypical, and his existing moles darkened; after he stopped, they progressively lightened. A 16-year-old girl with an inherited multiple-mole syndrome presented with multiple dark moles, some described as darkened, and an enlarging mole after self-injecting Melanotan 2 and attending a UV tanning studio.
One or a few individual cases. Cannot show whether an effect is general.
- Route: self-administered. The 2009 report does not state the route; the 2012 report describes self-injections.
- The 2009 report says only "synthetic alpha-MSH", not Melanotan II.
- The 2012 patient had familial atypical multiple mole melanoma (FAMMM) syndrome and used UV tanning, both independent reasons for mole changes.
- Single patients; product content was not analysed in either report as read.
- Animal researchSupportive / Low confidence
In mice, Melanotan II injected into the brain's ventricles reduced feeding in four models of overeating.
Intracerebroventricular Melanotan II inhibited feeding in fasted C57BL/6J mice, ob/ob mice, A(Y) mice and mice injected with neuropeptide Y. This is laboratory work on the brain's appetite pathways, not a test of weight loss.
Observed in animals. Animal results frequently fail to replicate in humans.
- Route: injection into the brain's ventricles, in mice. Not how people use it.
- No human study measured food intake or body weight. The only human signal is "decreased appetite" listed as a side effect in the 1998 trial of 10 men.
- Many other rodent feeding studies exist; only this one was read for this page.
- In-vitroSupportive / Moderate confidence
Laboratory analysis of vials sold online as injectable tanning products from three shops found 4.32 to 8.84 mg of Melanotan II per vial against a labelled 10 mg, with 4.1 to 5.9% unknown impurities in vials from two shops.
Every vial analysed contained less Melanotan II than its label claimed. A separate analysis of eight police-seized samples intended for the illicit bodybuilding market identified Melanotan II and bremelanotide among them. In Australia, TGA testing of five seized nasal spray bottles labelled 30 mg found between 22 mg and 54 mg.
Observed in cells or tissue outside a living organism.
- Route: not applicable. These are measurements of products, not of people.
- Three online shops in a 2015 study; a small sample from one period.
- The TGA figures are estimates based on the labelled volume of 20 mL per bottle. The TGA advisory was read in a browser by a person, because the TGA's website could not be reached from the research environment.
- Mechanistic reasoningSupportive / High confidence
Melanotan II is a cyclic seven-residue analogue of alpha-MSH. Bremelanotide shares its sequence and ring but ends in a free acid rather than an amide, and afamelanotide is a different, 13-residue analogue.
The investigators who first tested it in people describe Melanotan II as a lactam-bridged cyclic heptapeptide analogue of alpha-melanocyte stimulating hormone, and as a non-selective melanocortin receptor agonist. FDA's label for bremelanotide (Vyleesi) gives the same cyclic sequence with a free acid at the carboxyl end. FDA's label for afamelanotide (Scenesse) describes it as a synthetic peptide of 13 amino acids and a melanocortin 1 receptor agonist.
A plausible biological explanation, not a measured outcome.
- This is chemical identity, not an effect. Neither approved drug's trials are evidence about Melanotan II.
- A 2007 review co-written by two investigators from the Arizona trials calls bremelanotide, which it names PT-141, "the carboxylate derivative of MT-II". No source found describes it as a metabolite of Melanotan II.
- The literature sometimes conflates the names: a 2003 article writes "PT 141 (Melanotan II)", and many case reports say only "melanotan" without saying which peptide.
PMID 8637402PMID 11035391fda-label-vyleesi-2026PMID 17584130fda-label-scenesse-2026
- Mechanistic reasoningInsufficient evidence / Moderate confidence
No human study of Melanotan II has measured whether it protects against sunburn or skin cancer, although it has been marketed that way.
The one pigmentation study measured skin colour in 3 men. FDA records that a seller's website linked to articles reporting that Melanotan II "was developed for the purpose of protecting against skin cancer and rosacea", and Denmark's medicines agency described it as marketed as offering protection against the sun and preventing skin cancer.
A plausible biological explanation, not a measured outcome.
- Route: not applicable. This is the absence of a study, found by searching PubMed and ClinicalTrials.gov on 8 October 2026.
- An absence of studies is not evidence of protection or of harm.
- The Danish warning names "Melanotan" without saying which peptide.
PMID 8637402fda-debarment-proposal-manookiandkma-melanotan-warning-2011
Reported and theoretical risks
- Case reportmoderate
Nausea, sometimes severe
Nausea was reported in all three trials. In the 1996 pilot it was mild and needed no anti-nausea drug. In the 2000 crossover, 4 of 19 Melanotan II injections were followed by severe nausea. The group's pooled review gives severe nausea as 12.9% of subjects, a different denominator that cannot be reconciled with the per-injection figure from the abstracts.
- Case reportmild
Yawning, stretching, spontaneous erections, drowsiness and reduced appetite
Stretching and yawning were reported in all three trials. In the pilot, they appeared to coincide with spontaneous erections that came and went for 1 to 5 hours, and one of two men at the highest level had grade II somnolence and fatigue. Decreased appetite was reported more often than with placebo in the 1998 trial. All of these come from 23 men observed for hours or, at most, two weeks.
- Case reportunknown
Melanoma and changes in moles, with causation not established
Case reports describe melanoma, melanoma in situ, and new or darkening moles in people who used Melanotan II or products described as alpha-MSH. No study has measured melanoma incidence in users, and the most recent report's authors state that causality remains unproven and that tanning bed use was a major confounder. This page does not say Melanotan II raises melanoma risk, because no study has tested that.
- Case reportserious
Priapism requiring emergency treatment
Two case reports describe priapism, a prolonged erection, after injection under the skin. One names Melanotan II; the other says only melanotan. In one, low-flow priapism was treated with aspiration, irrigation and phenylephrine injected into the penis, and the man had not yet recovered erectile function four weeks later. In the other, the man needed an operation after initial treatment failed. Spontaneous erections were an expected effect in the trials, which makes the event plausible but does not show the product caused either case.
- Case reportserious
Systemic toxicity with muscle breakdown and kidney dysfunction
A 39-year-old man who injected Melanotan II bought online, to darken his skin in winter, developed what the authors describe as systemic toxicity including apparent sympathomimetic symptoms, rhabdomyolysis (muscle breakdown) and renal dysfunction. Mass spectrometry confirmed the injected product was Melanotan II, and his urine drug screen was positive for opiates, a co-exposure. FDA lists sympathomimetic toxidrome among events in published case reports. One case cannot establish cause.
- Mechanismserious
Posterior reversible encephalopathy syndrome
FDA names posterior reversible encephalopathy syndrome, a condition of brain swelling, among serious adverse events discussed in published case reports. The report itself could not be read for this page, so nothing is stated here beyond FDA's mention.
- Mechanismtheoretical
Compounded Melanotan II may provoke an immune response
FDA states that compounded drugs containing Melanotan II may pose a risk of immunogenicity for certain routes of administration, because of the potential for aggregation or peptide-related impurities. This is a regulator's reasoned concern, not a harm observed in a study.
- In-vitrounknown
Products do not contain what their labels say
Vials from three online shops held less Melanotan II than labelled, and vials from two shops held unidentified impurities. TGA testing found 22 mg to 54 mg across five bottles carrying the same 30 mg label, and the TGA says this inconsistency further increases the chance of adverse events.
- Mechanismunknown
There is no long-term human safety record
The longest trial lasted two weeks, all 23 participants were men, and there are no pregnancy data. Between 2011 and 2021 the MHRA received 13 suspected adverse reaction reports associated with melanotan II, and states that a report does not necessarily mean the drug caused the event and that the scheme is subject to under-reporting.
Regulatory status
Status differs by country and changes over time. Each entry is dated and sourced.
USFDAnot approved
In a 2016 debarment order against a man whose company sold it online, FDA describes Melanotan II as "an unapproved new drug" advertised "as an injectable tanning product". FDA's earlier proposal in the same case records a 2007 warning letter to the company and the owner's admission that it sold a drug that had not been approved by FDA.
As of 14 November 2016. Source
USFDAunclear
FDA's safety-risks page lists Melanotan II among bulk drug substances previously in category 2 whose nominations were withdrawn. Its concern remains published: "Compounded drugs containing Melanotan II may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism." The page gives no withdrawal date. A withdrawn nomination is neither an approval nor a ban.
As of 22 April 2026. Source
USFDAunclear
FDA's 503A bulk drug substance categories list updated on 14 May 2026 does not include Melanotan II in category 1, 2 or 3.
As of 14 May 2026. Source
USFDAunclear
FDA's Pharmacy Compounding Advisory Committee page lists Melanotan II among substances "being considered for inclusion on the 503A bulks list", at a meeting FDA will host before the end of February 2027, with time and location still to be scheduled. This sits awkwardly with the 503A list of 14 May 2026, which carries Melanotan II in no category. No FDA document found explains the difference.
As of 15 April 2026. Source
AUTGAnot approved
The TGA states that Melanotan II is a prescription-only medicine in Australia, is not approved for use as a tanning agent, and that no product containing it is included in the Australian Register of Therapeutic Goods or approved for supply. The advisory of 17 August 2026 was read in a browser by a person on 8 October 2026, because the TGA's website could not be reached from the environment used to research this page.
As of 17 August 2026. Source
GBMHRAunclear
In a freedom of information reply of 17 April 2024, the MHRA states that products containing Melanotan II "are not always classified as medicines": they "are classified as medicines if they are injectable or pens", while a nasal spray "will be determined as a medicine only if sold with claims to treat or prevent disease". It adds that "the sale, supply and advertising of unauthorised medicines is not permitted under the Human Medicines Regulations". An earlier reply, of December 2021, had said injectable tanning products containing melanotan II "are not automatically medicines"; the 2024 reply is the more recent position.
As of 17 April 2024. Source
DKDanish Medicines Agencynot approved
In a 2011 warning repeating one from 2008, the Danish Medicines Agency calls the product illegal and states that it "is not authorised in Denmark, Europe or the United States". The warning names "Melanotan" throughout and does not say whether it means Melanotan I or Melanotan II.
As of 20 June 2011. Source
Research and analysis
Related peptides
- AfamelanotideA synthetic alpha-MSH analogue approved as an implant for one rare light disease in adults
Sources
- 1. Dorr RT et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 1996. PubMed 8637402
- 2. Wessells H et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research. 2000. PubMed 11035391
- 3. VYLEESI (bremelanotide injection) prescribing information. U.S. Food and Drug Administration (openFDA drug label). 2026. View source(open access)
- 4. King SH et al. Melanocortin receptors, melanotropic peptides and penile erection. Current Topics in Medicinal Chemistry. 2007. PubMed 17584130
- 5. SCENESSE (afamelanotide) implant prescribing information, NDA 210797. U.S. Food and Drug Administration (openFDA drug label). 2026. View source(open access)
- 6. Wessells H et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. The Journal of Urology. 1998. PubMed 9679884
- 7. Wessells H et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000. PubMed 11018622
- 8. Proposal to Debar; Notice of Opportunity for Hearing, Docket No. FDA-2015-N-4169 (Edward Manookian, Melanocorp). U.S. Food and Drug Administration, Office of Enforcement & Import Operations. 2015. View source(open access)
- 9. Warning against the tanning product Melanotan. Danish Medicines Agency (Lægemiddelstyrelsen). 2011. View source(open access)
- 10. Vadner DJ, Smith S. Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use. JAAD Case Reports. 2026. PubMed 42328529(open access)
- 11. Yassin Alsabbagh A, Bhujel N, Singh RP. Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?. International Journal of Oral and Maxillofacial Surgery. 2025. PubMed 40210573
- 12. Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014. PubMed 24355990
- 13. Habbema L et al. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology. 2017. PubMed 28266027
- 14. Cardones AR, Grichnik JM. alpha-Melanocyte-stimulating hormone-induced eruptive nevi. Archives of Dermatology. 2009. PubMed 19380666
- 15. Sivyer GW. Changes of melanocytic lesions induced by Melanotan injections and sun bed use in a teenage patient with FAMMM syndrome. Dermatology Practical & Conceptual. 2012. PubMed 23785612(open access)
- 16. Fan W et al. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997. PubMed 8990120
- 17. Breindahl T et al. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Testing and Analysis. 2015. PubMed 24771717
- 18. Mestria S et al. LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs. Drug Testing and Analysis. 2021. PubMed 33245851
- 19. Melanotan II tanning peptide products found to be inconsistently dosed. Therapeutic Goods Administration. 2026. View source(open access)
- 20. Dreyer BA, Amer T, Fraser M. Melanotan-induced priapism: a hard-earned tan. BMJ Case Reports. 2019. PubMed 30796078
- 21. Mallory CW, Lopategui DM, Cordon BH. Melanotan Tanning Injection: A Rare Cause of Priapism. Sexual Medicine. 2021. PubMed 33460908(open access)
- 22. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. View source(open access)
- 23. Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical Toxicology. 2012. PubMed 23121206
- 24. FOI 21/1237: Yellow Card reports for melanotan II products, 2011 to 2021. Medicines and Healthcare products Regulatory Agency. 2021. View source(open access)
- 25. Edward Manookian (Also Known as Ed Manning): Debarment Order. Federal Register (Food and Drug Administration). 2016. View source(open access)
- 26. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, updated May 14, 2026. U.S. Food and Drug Administration. 2026. View source(open access)
- 27. Meeting of the Pharmacy Compounding Advisory Committee (to be scheduled before the end of February 2027). U.S. Food and Drug Administration. 2026. View source(open access)
- 28. FOI 24/274: Side effects reports of melanotan II products. Medicines and Healthcare products Regulatory Agency. 2024. View source(open access)